Cargando…
Precision Medicine in Rare Diseases
Rare diseases are those that have a low prevalence in the population (less than 5 individuals per 10,000 inhabitants). However, infrequent pathologies affect a large number of people, since according to the World Health Organization (WHO), there are about 7000 rare diseases that affect 7% of the wor...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709101/ https://www.ncbi.nlm.nih.gov/pubmed/33202892 http://dx.doi.org/10.3390/diseases8040042 |
_version_ | 1783617680956194816 |
---|---|
author | Villalón-García, Irene Álvarez-Córdoba, Mónica Suárez-Rivero, Juan Miguel Povea-Cabello, Suleva Talaverón-Rey, Marta Suárez-Carrillo, Alejandra Munuera-Cabeza, Manuel Sánchez-Alcázar, José Antonio |
author_facet | Villalón-García, Irene Álvarez-Córdoba, Mónica Suárez-Rivero, Juan Miguel Povea-Cabello, Suleva Talaverón-Rey, Marta Suárez-Carrillo, Alejandra Munuera-Cabeza, Manuel Sánchez-Alcázar, José Antonio |
author_sort | Villalón-García, Irene |
collection | PubMed |
description | Rare diseases are those that have a low prevalence in the population (less than 5 individuals per 10,000 inhabitants). However, infrequent pathologies affect a large number of people, since according to the World Health Organization (WHO), there are about 7000 rare diseases that affect 7% of the world’s population. Many patients with rare diseases have suffered the consequences of what is called the diagnostic odyssey, that is, extensive and prolonged serial tests and clinical visits, sometimes for many years, all with the hope of identifying the etiology of their disease. For patients with rare diseases, obtaining the genetic diagnosis can mean the end of the diagnostic odyssey, and the beginning of another, the therapeutic odyssey. This scenario is especially challenging for the scientific community, since more than 90% of rare diseases do not currently have an effective treatment. This therapeutic failure in rare diseases means that new approaches are necessary. Our research group proposes that the use of precision or personalized medicine techniques can be an alternative to find potential therapies in these diseases. To this end, we propose that patients’ own cells can be used to carry out personalized pharmacological screening for the identification of potential treatments. |
format | Online Article Text |
id | pubmed-7709101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77091012020-12-03 Precision Medicine in Rare Diseases Villalón-García, Irene Álvarez-Córdoba, Mónica Suárez-Rivero, Juan Miguel Povea-Cabello, Suleva Talaverón-Rey, Marta Suárez-Carrillo, Alejandra Munuera-Cabeza, Manuel Sánchez-Alcázar, José Antonio Diseases Review Rare diseases are those that have a low prevalence in the population (less than 5 individuals per 10,000 inhabitants). However, infrequent pathologies affect a large number of people, since according to the World Health Organization (WHO), there are about 7000 rare diseases that affect 7% of the world’s population. Many patients with rare diseases have suffered the consequences of what is called the diagnostic odyssey, that is, extensive and prolonged serial tests and clinical visits, sometimes for many years, all with the hope of identifying the etiology of their disease. For patients with rare diseases, obtaining the genetic diagnosis can mean the end of the diagnostic odyssey, and the beginning of another, the therapeutic odyssey. This scenario is especially challenging for the scientific community, since more than 90% of rare diseases do not currently have an effective treatment. This therapeutic failure in rare diseases means that new approaches are necessary. Our research group proposes that the use of precision or personalized medicine techniques can be an alternative to find potential therapies in these diseases. To this end, we propose that patients’ own cells can be used to carry out personalized pharmacological screening for the identification of potential treatments. MDPI 2020-11-13 /pmc/articles/PMC7709101/ /pubmed/33202892 http://dx.doi.org/10.3390/diseases8040042 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Villalón-García, Irene Álvarez-Córdoba, Mónica Suárez-Rivero, Juan Miguel Povea-Cabello, Suleva Talaverón-Rey, Marta Suárez-Carrillo, Alejandra Munuera-Cabeza, Manuel Sánchez-Alcázar, José Antonio Precision Medicine in Rare Diseases |
title | Precision Medicine in Rare Diseases |
title_full | Precision Medicine in Rare Diseases |
title_fullStr | Precision Medicine in Rare Diseases |
title_full_unstemmed | Precision Medicine in Rare Diseases |
title_short | Precision Medicine in Rare Diseases |
title_sort | precision medicine in rare diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709101/ https://www.ncbi.nlm.nih.gov/pubmed/33202892 http://dx.doi.org/10.3390/diseases8040042 |
work_keys_str_mv | AT villalongarciairene precisionmedicineinrarediseases AT alvarezcordobamonica precisionmedicineinrarediseases AT suarezriverojuanmiguel precisionmedicineinrarediseases AT poveacabellosuleva precisionmedicineinrarediseases AT talaveronreymarta precisionmedicineinrarediseases AT suarezcarrilloalejandra precisionmedicineinrarediseases AT munueracabezamanuel precisionmedicineinrarediseases AT sanchezalcazarjoseantonio precisionmedicineinrarediseases |